TY - JOUR
T1 - Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes
AU - O'Neal, Wanda K.
AU - Gallins, Paul
AU - Pace, Rhonda G.
AU - Dang, Hong
AU - Wolf, Whitney E.
AU - Jones, Lisa C.
AU - Guo, Xueliang
AU - Zhou, Yi Hui
AU - Madar, Vered
AU - Huang, Jinyan
AU - Liang, Liming
AU - Moffatt, Miriam F.
AU - Cutting, Garry R.
AU - Drumm, Mitchell L.
AU - Rommens, Johanna M.
AU - Strug, Lisa J.
AU - Sun, Wei
AU - Stonebraker, Jaclyn R.
AU - Wright, Fred A.
AU - Knowles, Michael R.
N1 - Funding Information:
The work described in this paper was funded by the US National Heart, Lung, and Blood Institute (R01HL095396, M.R.K. and F.A.W.); the US National Institute of Diabetes and Digestive and Kidney Diseases (P30DK065988, W.K.O.); the US Cystic Fibrosis Foundation (RDP-026, W.K.O.); the Canadian Institutes of Health Research (MOP-258916, L.J.S.); and CF Canada (L.J.S.). Enrollment and sample collection was funded by the US Cystic Fibrosis Foundation (KNOWLE00A0, M.R.K.) and the US NIH (HL068890, M.R.K.), with additional analysis support from MH101819 (F.A.W.). Funds were provided through Aetna/U.S. Healthcare Chair (G.R.C.). Additionally, funds for genome-wide genotyping were generously provided by the US Cystic Fibrosis Foundation (CFF). The authors would like to thank the Cystic Fibrosis Foundation for the use of CF Foundation Patient Registry data to conduct this study. Additionally, we would like to thank the CF-affected individuals and their families, care providers, and clinic coordinators at CF Centers throughout the United States for their contributions to the CF Foundation Patient Registry. The authors would also like to thank the Canadian Consortium for CF genetic studies, the University of North Carolina DNA Laboratory, and the following for their contributions: for manuscript preparation, Syanne Olson; for recruitment and data entry, Sonya Adams, Colette Bucur, Leia Charnin, John Dunn, Patricia Miller, Sarah A. Norris, and Sally D. Wood; for genotyping, Rodney Gilmore; for data analysis, Anthony T. Dang, Michael V. Patrone, Clayton W. Commander, Evan J. Hawbaker, and Aaron Webel; and for bioinformatics, Hemant Kelkar, Tom Randall, and Annie Xu.
Publisher Copyright:
© 2015 The American Society of Human Genetics.
PY - 2015/2/5
Y1 - 2015/2/5
N2 - Variation in cystic fibrosis (CF) phenotypes, including lung disease severity, age of onset of persistent Pseudomonas aeruginosa (P. aeruginosa) lung infection, and presence of meconium ileus (MI), has been partially explained by genome-wide association studies (GWASs). It is not expected that GWASs alone are sufficiently powered to uncover all heritable traits associated with CF phenotypic diversity. Therefore, we utilized gene expression association from lymphoblastoid cells lines from 754 p.Phe508del CF-affected homozygous individuals to identify genes and pathways. LPAR6, a G protein coupled receptor, associated with lung disease severity (false discovery rate q value = 0.0006). Additional pathway analyses, utilizing a stringent permutation-based approach, identified unique signals for all three phenotypes. Pathways associated with lung disease severity were annotated in three broad categories: (1) endomembrane function, containing p.Phe508del processing genes, providing evidence of the importance of p.Phe508del processing to explain lung phenotype variation; (2) HLA class I genes, extending previous GWAS findings in the HLA region; and (3) endoplasmic reticulum stress response genes. Expression pathways associated with lung disease were concordant for some endosome and HLA pathways, with pathways identified using GWAS associations from 1,978 CF-affected individuals. Pathways associated with age of onset of persistent P. aeruginosa infection were enriched for HLA class II genes, and those associated with MI were related to oxidative phosphorylation. Formal testing demonstrated that genes showing differential expression associated with lung disease severity were enriched for heritable genetic variation and expression quantitative traits. Gene expression provided a powerful tool to identify unrecognized heritable variation, complementing ongoing GWASs in this rare disease.
AB - Variation in cystic fibrosis (CF) phenotypes, including lung disease severity, age of onset of persistent Pseudomonas aeruginosa (P. aeruginosa) lung infection, and presence of meconium ileus (MI), has been partially explained by genome-wide association studies (GWASs). It is not expected that GWASs alone are sufficiently powered to uncover all heritable traits associated with CF phenotypic diversity. Therefore, we utilized gene expression association from lymphoblastoid cells lines from 754 p.Phe508del CF-affected homozygous individuals to identify genes and pathways. LPAR6, a G protein coupled receptor, associated with lung disease severity (false discovery rate q value = 0.0006). Additional pathway analyses, utilizing a stringent permutation-based approach, identified unique signals for all three phenotypes. Pathways associated with lung disease severity were annotated in three broad categories: (1) endomembrane function, containing p.Phe508del processing genes, providing evidence of the importance of p.Phe508del processing to explain lung phenotype variation; (2) HLA class I genes, extending previous GWAS findings in the HLA region; and (3) endoplasmic reticulum stress response genes. Expression pathways associated with lung disease were concordant for some endosome and HLA pathways, with pathways identified using GWAS associations from 1,978 CF-affected individuals. Pathways associated with age of onset of persistent P. aeruginosa infection were enriched for HLA class II genes, and those associated with MI were related to oxidative phosphorylation. Formal testing demonstrated that genes showing differential expression associated with lung disease severity were enriched for heritable genetic variation and expression quantitative traits. Gene expression provided a powerful tool to identify unrecognized heritable variation, complementing ongoing GWASs in this rare disease.
UR - http://www.scopus.com/inward/record.url?scp=84925082500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925082500&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2014.12.022
DO - 10.1016/j.ajhg.2014.12.022
M3 - Article
C2 - 25640674
AN - SCOPUS:84925082500
SN - 0002-9297
VL - 96
SP - 318
EP - 328
JO - American journal of human genetics
JF - American journal of human genetics
IS - 2
ER -